jeudi 16 avril 2015

Onco Actu du 16 avril 2015

1. Biologie

From snapshot to family tree – writing the evolutionary rule book of cancer [Cancer Research UK]

Scientists decipher key steps in cancer development to improve treatment [Cancer Research UK]

4.2 Dép., diag. & prono. - Génome

Personal Genome Diagnostics Study Highliths Limitations of Tumor-Only Sequencing for Cancer [PGD]

Study: Genetic Tests of Tumors Often Gives False Results [Scientific American]

Personalizing Cancer Treatment With Genetic Tests Can Be Tricky [NPR]

Study: Genetic Tests of Tumors Often Gives False Results [Scientific American]

U.S. study calls into question tests that sequence tumor genes [Reuters]

5. Traitements

Inhibitor for Abnormal Protein Points the Way to More Selective Cancer Drugs [Caltech]

5.10 Traitements - Essais

WHO Joins the Push for Greater Disclosure of Clinical Trial Data [Wall Street Journal]

WHO Statement on Reporting Clinical Trials [Science-Based Medicine]

5.12 Immunothérapies

Immunotherapy Opens Two Fronts, Innate and Adaptive, against Cancer [GEN]

5.2 Pharma

Pfizer Announces PALOMA-3 Trial For IBRANCE® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy [Pfizer]

Pfizer's Ibrance shines in latest breast cancer study [FiercePharma]

Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in prostate cancer [Ipsen]

Data in The Lancet show Novartis drug Arzerra® plus chlorambucil improved median progression-free survival by 71% in CLL patients [Novartis]

AstraZeneca science is on the move, one year on from Pfizer bid [Reuters]

Approved Pfizer breast cancer drug impresses in latest study [Reuters]

5.2.1 Pharma - Partenariats

Cancer Research Technology and Medivir collaborate to develop new class of cancer drugs [Cancer Research UK]

5.3 Traitements - FDA, EMA,...

Tremelimumab granted Orphan Drug Designation by US FDA for treatment of malignant mesothelioma [AstraZeneca]

5.4 Traitements - Economie

Innocrin Pharmaceuticals Lands $28M for Prostate, Breast Cancer Trials [Xconomy]

Xbiotech’s $76M Offering Sets Course for Late-Stage Cancer Studies [Xconomy]

Cancer Immunotherapy Remains Hot as Aduro Biotech Doubles in Value On IPO Debut [TheStreet]

5.9 AACR

American Assoc. for Cancer Research - What to look forward to [Behind the Bench]

Bayer to Present New Data on Advancing Oncology Portfolio [Bayer]

6. Lutte contre les cancers

New consortium to develop more personalised treatment for bowel cancer patients [PHG Foundation]

The Medical University of Innsbruck is coordinating the EU research project on personalised cancer immunotherapy [AlphaGalileo]

6.10 Politiques

Bill Clinton Speaks About Science And Cancer Research At Charity Event [Forbes]

6.6 Publications

Gynecologic cancer researcher earns eighth retraction [Retraction Watch]

6.7 DMP, Big Data & applis

Revisiting The Central Dogma Of Precision Medicine [Forbes]

Big Data Key to Precision Medicine's Success [Weill Cornell Medical College]

EMR 2015: The Market for Electronic Medical Records [Market Research Report]

6.9 Controverses

Battle over CRISPR Gene Editing Patents [MIT Technology Review]